LakeShore Biopharma Files 6-K Report
Ticker: LSBWF · Form: 6-K · Filed: Oct 25, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, reporting
TL;DR
LAKESHORE BIOPHARMA (LSPB) filed a 6-K, standard foreign issuer report.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on October 25, 2024. The filing is a report of a foreign private issuer for the month of October 2024. The company is incorporated in E9 and has its principal executive offices in Beijing, PRC.
Why It Matters
This filing provides routine updates for foreign private issuers, informing investors about the company's ongoing reporting status.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former Company Name
- YishengBio Co., Ltd (company) — Former Company Name
- 001-41598 (dollar_amount) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What is the filing date of this report?
This report was filed on October 25, 2024.
What are the former names of LakeShore Biopharma Co., Ltd.?
The company was formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd.
Where are the principal executive offices of LakeShore Biopharma Co., Ltd. located?
The principal executive offices are located in Daxing District, Beijing, PRC.
Does LakeShore Biopharma Co., Ltd. file annual reports under Form 20-F or 40-F?
LakeShore Biopharma Co., Ltd. files annual reports under Form 20-F.
Filing Stats: 254 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-10-25 08:40:26
Filing Documents
- ea0218644-6k_lakeshore.htm (6-K) — 12KB
- ea021864401ex99-1_lakeshore.htm (EX-99.1) — 12KB
- 0001213900-24-090530.txt ( ) — 25KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INCORPORATION BY REFERENCE This current report on Form 6-K, including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the LakeShore Biopharma Co., Ltd registration statements on Form S-8 (File No. 333-279544 and File No. 333-273165 ) and to be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. 1 EXHIBITS Exhibit No. Description 99.1 Press Release dated October 25, 2024 – LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: October 25, 2024 3